UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January~~February 146, 2020

FOAMIX PHARMACEUTICALS LTD.

(Exact name of registrant as specified in its charter)

Israel	001-36621	N/A
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2 Holzman Street,

Weizmann Science Park

Rehovot, Israel

7670402

(Address of principal executive offices)

(Zip Code)

+972-8-9316233

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Ticker symbol(s)	Name of each exchange on which registered
Ordinary Shares, par value NIS 0.16 per share	FOMX	Nasdaq Global Stock Market

Title of each class	Ticker symbol(s)	Name of each exchange on which registered
Ordinary Shares, par value NIS 0.16 per share	FOMX	Nasdaq Global Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 75.0107 ~~Regulation~~Submission FDof ~~Disclosure~~Matters to a Vote of Security Holders.

On ~~January~~February 146, 2020, Foamix Pharmaceuticals Ltd. (“Foamix” or the “Company”) ~~issued~~held aan ~~press~~extraordinary ~~release~~general ~~entitled~~meeting ~~“Foamix~~of ~~Announces~~shareholders ~~AMZEEQTM~~ (~~minocycline)~~the ~~Achievement~~“Extraordinary Meeting”), ofat ~~Preferred~~which ~~Status~~a onquorum ~~Express~~was ~~Scripts~~present, ~~National~~to ~~Preferred~~vote ~~Formulary,~~on ~~One~~matters ofrelated to the ~~Largest~~previously ~~Commercial~~announced ~~Formularies~~merger inwith ~~the~~Giants UMerger Subsidiary Ltd.S (“Merger Sub”), a wholly-owned subsidiary of Menlo Therapeutics Inc. (“Menlo” ). A ~~copy~~summary of the ~~press~~voting results ~~release~~for the following proposals, each of which is ~~attached~~described asin ~~Exhibit~~detail ~~99.1~~in the Company’s definitive proxy statement dated January 7, 2020, which was first mailed to ~~this~~the ~~report.~~Company’s shareholders on or about January 8, 2020, is set forth below:

~~The~~Proposal ~~information in this Item 7.01 and Exhibit 99.~~1 hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

~~Item~~Foamix’s 9shareholders adopted the Agreement and Plan of Merger, dated as of November 10, 2019 (as amended by Amendment No.01 ~~Financial~~1 ~~Statements~~to the Agreement and ~~Exhibits~~Plan of Merger, dated as of December 4, 2019), by and among Foamix, Menlo and Merger Sub and approved the merger of Merger Sub with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo (the “Merger”).

(d) Exhibits

Votes For

Votes Against

Abstentions

Broker Non-Votes

29,287,245

1,578,432

160,978

Exhibit No.		Description
99.1		Press release entitled “Foamix Announces AMZEEQTM (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.,” dated January 14, 2020.

As required by Israeli law, Proposal 1 was approved by shareholders holding a majority of the ordinary shares voted on such proposal who affirmatively confirmed that they were not any of (i) Menlo, (ii) Merger Sub, or (iii) (a) a person holding, directly or indirectly, either (x) 25% or more of the voting rights of Menlo or Merger Sub or (y) the right to appoint 25% or more of the directors of Menlo or Merger Sub, (b) a person or entity acting on behalf of Menlo, Merger Sub or a person described in subsection (a) above or (c) one of such person’s spouse, siblings, parents, grandparents, descendants, spouse’s descendants, siblings or parents or the spouse of any such person, or a corporation controlled by any one or more of such persons or entities or by Menlo or Merger Sub.

~~SIGNATURES~~Proposal 2.

~~Pursuant~~Foamix’s toshareholders ~~the~~approved, ~~requirements~~on ofan ~~the~~advisory, ~~Securities~~non-binding ~~Exchange Act of 1934~~basis, the ~~registrant~~compensation ~~has~~that ~~duly~~may ~~caused~~be ~~this~~paid ~~report~~or tobecome bepayable ~~signed~~to onFoamix’s ~~its~~named ~~behalf~~executive byofficers ~~the~~in ~~undersigned~~connection ~~hereunto~~with ~~duly~~the ~~authorized~~Merger.

Date: January 14, 2020

Votes For

Votes Against

Abstentions

Broker Non-Votes

28,108,621

2,700,402

217,632

~~FOAMIX~~Item ~~PHARMACEUTICALS LTD~~8.01 ~~By:~~Other ~~/s/ Mutya Harsch Mutya Harsch Chief Legal Officer~~Events.

On February 6, 2020, Foamix and Menlo issued a joint press release entitled “Foamix and Menlo Announce Shareholder Approval of Proposed Merger.” A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Foamix and Menlo expect the Merger to close in early March 2020.

Important Additional Information and Where to Find It

On January 6, 2020, Menlo filed a Registration Statement on Form S-4 containing a joint proxy statement/prospectus of Menlo and Foamix and other documents concerning the proposed merger with the Securities and Exchange Commission (the “SEC”). The registration statement has been declared effective by the SEC. Foamix mailed the definitive proxy statement/prospectus and a proxy card to each stockholder entitled to vote at the special meeting relating to the proposed merger. On January 28, 2020, Menlo filed with the SEC an amendment to the Registration Statement on Form S-4. Foamix and Menlo may also file other relevant documents with the SEC regarding the proposed merger. This communication is not a substitute for the joint proxy statement/prospectus or Registration Statement or any other document which Menlo or Foamix may file with the SEC. MENLO’S AND FOAMIX’S RESPECTIVE STOCKHOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY AND ANY OTHER DOCUMENTS FILED BY EACH OF MENLO AND FOAMIX WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER AND THE PARTIES TO THE PROPOSED MERGER. Security holders may obtain a free copy of the joint proxy statement/prospectus and other documents filed by Menlo and Foamix with the SEC at the SEC’s website at www.sec.gov. Investors and stockholders will also be able to obtain a free copy of the joint proxy statement/prospectus and other documents containing important information about Menlo and Foamix through the website maintained by the SEC at www.sec.gov. Menlo and Foamix make available free of charge at www.menlotherapeutics.com and www.foamix.com, respectively (in the “ Investor Relations” section), copies of materials they file with, or furnish to, the SEC.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Words such as “ anticipate,” “ expect,” “ project,” “ intend,” “ believe,” and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. Such factors include, but are not limited to: (i) conditions to the closing of the merger may not be satisfied; (ii) the merger may involve unexpected costs, liabilities or delays; (iii) the effect of the announcement of the merger on the ability of Menlo or Foamix to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom Menlo or Foamix does business, or on Menlo’s or Foamix’s operating results and business generally; (iv) Menlo’s or Foamix’s respective businesses may suffer as a result of uncertainty surrounding the merger and disruption of management’s attention due to the merger; (v) the outcome of any legal proceedings related to the merger; (vi) Menlo or Foamix may be adversely affected by other economic, business, and/or competitive factors; (vii) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; (viii) risks that the merger disrupts current plans and operations and the potential difficulties in employee retention as a result of the merger; (ix) the risk that Menlo or Foamix may be unable to obtain governmental and regulatory approvals required for the transaction, or that required governmental and regulatory approvals may delay the transaction or result in the imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; and (x) other risks to consummation of the merger, including the risk that the merger will not be consummated within the expected time period or at all. Additional factors that may affect the future results of Menlo and Foamix are set forth in their respective filings with the SEC, including each of Menlo’s or Foamix’s most recently filed Annual Report on Form 10- K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the SEC’s website at www.sec.gov. See in particular Item 1A of Part II of Menlo’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 under the heading “Risk Factors” and Item 1A of Part II of Foamix’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 under the heading “Risk Factors.” The risks and uncertainties described above and in Menlo’s most recent Quarterly Report on Form 10-Q and Foamix’s most recent Quarterly Report on Form 10-Q are not exclusive and further information concerning Menlo and Foamix and their respective businesses, including factors that potentially could materially affect its business, financial condition or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements. Readers should also carefully review the risk factors described in other documents that Menlo and Foamix file from time to time with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Except as required by law, Menlo and Foamix assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Press release entitled “Foamix and Menlo Announce Shareholder Approval of Proposed Merger,” dated February 6, 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 6, 2020

	FOAMIX PHARMACEUTICALS LTD.

	By:	/s/ Mutya Harsch
		Mutya Harsch
		Chief Legal Officer

Filing Compare · Foamix Pharmaceuticals Ltd.